University of California

Sang-Mo Kang

Lewis L Lanier

Steinunn Baekkeskov

Andries Erik Braat

Peter G Stock

The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.

Modulation of NKG2D for treating or preventing solid organ allograft rejection

This invention generally provides polypeptides comprising a noncleavable form of a Fas ligand and having a capacity to activate a Fas receptor-mediated pathway involved in cell death, pharmaceutical compositions of such polypeptides, nucleic acids encoding such polypeptides, and cell lines capable of expressing these nucleic acids. Also provided are therapeutic and prophylactic methods of using such polypeptides, compositions, and cells lines for treating patients suffering from disorders resulting from dysregulation or inappropriate stimulation of the Fas receptor-mediated pathway.

Growing community of inventors

San Francisco, CA, United States of America

Sang-Mo Kang